- Home
- BIIB vs UMC Comparison
BIIB vs UMC Comparison
Compare BIIB & UMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- UMC
- Stock Information
- Founded
- BIIB 1978
- UMC 1980
- Country
- BIIB United States
- UMC Taiwan
- Employees
- BIIB 7605
- UMC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- UMC Semiconductors
- Sector
- BIIB Health Care
- UMC Technology
- Exchange
- BIIB Nasdaq
- UMC Nasdaq
- Market Cap
- BIIB 18.8B
- UMC 19.5B
- IPO Year
- BIIB 1991
- UMC 2000
- Fundamental
- Price
- BIIB $131.20
- UMC $7.62
- Analyst Decision
- BIIB Buy
- UMC Sell
- Analyst Count
- BIIB 26
- UMC 4
- Target Price
- BIIB $194.95
- UMC $7.40
- AVG Volume (30 Days)
- BIIB 1.7M
- UMC 9.9M
- Earning Date
- BIIB 05-01-2025
- UMC 04-23-2025
- Dividend Yield
- BIIB N/A
- UMC 6.09%
- EPS Growth
- BIIB 26.39
- UMC N/A
- EPS
- BIIB 10.12
- UMC 0.11
- Revenue
- BIIB $9,816,400,000.00
- UMC $7,078,482,907.00
- Revenue This Year
- BIIB N/A
- UMC $8.80
- Revenue Next Year
- BIIB N/A
- UMC $7.57
- P/E Ratio
- BIIB $12.83
- UMC $14.70
- Revenue Growth
- BIIB 1.59
- UMC 5.64
- 52 Week Low
- BIIB $110.04
- UMC $5.61
- 52 Week High
- BIIB $238.00
- UMC $9.00
- Technical
- Relative Strength Index (RSI)
- BIIB 59.82
- UMC 53.26
- Support Level
- BIIB $123.97
- UMC $7.68
- Resistance Level
- BIIB $132.94
- UMC $7.86
- Average True Range (ATR)
- BIIB 3.49
- UMC 0.12
- MACD
- BIIB 1.04
- UMC -0.05
- Stochastic Oscillator
- BIIB 88.37
- UMC 16.15
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About UMC United Microelectronics Corporation (NEW)
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 5% market share in 2024 after TSMC and SMIC. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the us, and South Korea. UMC features a diverse customer base that includes Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx, and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.